Twitter Still Looking for a Turnaround With Newest Board Addition
Effective immediately, Bret Taylor, CEO and co-founder of Quip, will join the Twitter board. Twitter is looking to bring some of his expertise to the table.
All Work
Chris Lange
Amedica Gears Up for Secondary Offering
Amedica expects to gain about $11 million in gross proceeds from an underwritten secondary offering. The entire offering is valued up to more than $12 million.
What to Expect From Walgreens Earnings
Walgreens Boots Alliance is scheduled to report its fiscal third-quarter financial results before the markets open on Wednesday.
AdvancePierre Foods Announces Potential Pricing for IPO
AdvancePierre Foods expects to price more than 18 million shares in the range of $20 to $23 per share for an initial public offering valued up to nearly $492 million.
Why Credit Suisse Sees AK Steel, Kellogg, Whole Foods and Others as Key Contrarian Stocks to Buy
Credit Suisse recently screened its current U.S. coverage universe in an effort to identify companies where its analysts’ views differed from that of Wall Street
Why Lennar May Offer the Most Upside of All Homebuilders
Independent research firm Argus has initiated coverage of homebuilder Lennar with a Buy rating and a $59 price target.
Yeti Files for IPO
Yeti Holdings has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Insys Soars on Huge FDA Win
Insys Therapeutics announced that the FDA has approved its dronabinol oral solution, Syndros, for use in treating anorexia associated with weight loss in patients with AIDS.
Top 3 Earnings Reports for the Coming Week
After the fallout and tentative recovery from the Brexit, the markets have not necessarily set a new direction. The coming week is a shortened trading week with the July 4th holiday and as a…
4 Companies That Destroyed Shareholders Despite a Brexit Recovery
Despite Brexit absolutely rocking the market over a week ago, the broad markets made a solid comeback leading most people to believe that this was just one big head fake. Some companies made runs in…
How Major Pharma Is Faring After the Brexit
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity to buy…
How Major Gold Stocks Are Responding to the Brexit
Gold has been on an absolute tear in 2016, especially considering the currency fears that many had going into the Brexit vote. Now more than ever investors were looking to hedge their portfolios with…
The Top 5 Performing Dow Stocks Coming Out of the Brexit
Looking at what was a brief but massive fallout within broad markets, we are realizing that the Brexit provided a very attractive entry point into a fair number of industries. The Dow Jones Industrial…
How the Top US Money Center Banks Are Responding to the Brexit
Watching the massive fallout and then recovery within broad markets, we are beginning to realize that the Brexit provided a very attractive entry point into a fair number of industries. Granted, the Brexit did pull…
The 4 Biggest Utilities Winning After Brexit
As the broad markets are recovering, we are starting to realize that the Brexit was a great opportunity to buy into the markets. The Brexit pulled markets back across the board. However, after a…
Mobileye Partners Up to Pioneer Autonomous Vehicle
Mobileye N.V. (NYSE: MBLY) is making waves in the market on Friday after the company announced a partnership with BMW and Intel Corp. (NASDAQ: INTC) to help pioneer an autonomous driving vehicle. The companies…
Why Array Is Making a Run
Array BioPharma Inc. (NASDAQ: ARRY) is watching its shares make a handy gain on Friday after making a key U.S. Food and Drug Administration (FDA) submission. The company announced the submission of a New…
Micron Falls Flat on Mixed Earnings
Micron Technology, Inc. (NASDAQ: MU) reported fiscal third-quarter financial results after the markets closed on Thursday. The company said that it had a net loss of $0.08 per share on $2.90 billion in revenue.…
Ampio Crashes After Late-Stage Trial Failure
Ampio Pharmaceuticals, Inc. (NYSEMKT: AMPE) is watching its shares get cut in half on Thursday after news of a failed late-stage trial. The company announced the results of its Ampion PIVOT clinical trial as well…
Bioventus Files for IPO
Bioventus Inc. filed a Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. There were no pricing details given in the filing but the offering is valued up to…